ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+30.86%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$57.5M
AUM Growth
+$57.5M
(+5.4%)
Cap. Flow
-$4.19M
Cap. Flow
% of AUM
-7.28%
Top 10 Holdings %
Top 10 Hldgs %
78.54%
Holding
23
New
4
Increased
9
Reduced
7
Closed
3
Top Buys
| 1 |
PTC Therapeutics
PTCT
|
$3.66M |
| 2 |
Amicus Therapeutics
FOLD
|
$2.88M |
| 3 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$2.51M |
| 4 |
IPXL
Impax Laboratories, Inc.
IPXL
|
$2.23M |
| 5 |
NovoCure
NVCR
|
$1.34M |
Top Sells
| 1 |
Teva Pharmaceuticals
TEVA
|
$4.19M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
$4.01M |
| 3 |
ALR
Alere Inc
ALR
|
$2.66M |
| 4 |
Quest Diagnostics
DGX
|
$2.55M |
| 5 |
Eli Lilly
LLY
|
$2.08M |
Sector Composition
| 1 | Healthcare | 77.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PTC Therapeutics
PTCT
$3.92B
| $7.95M | 13.83% | 567,683 +261,033 | +85% | +$3.66M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $5.69M | 9.89% | 150,651 +66,625 | +79% | +$2.51M |
|
3
Bio-Rad Laboratories Class A
BIO
$8.06B
| $5.03M | 8.74% | 30,687 -342 | -1% | -$56K |
|
|
4
Amicus Therapeutics
FOLD
$2.34B
| $4.58M | 7.96% | 618,317 +388,691 | +169% | +$2.88M |
|
5
Centene
CNC
$14.3B
| $4.54M | 7.9% | 67,856 -14,279 | -17% | -$956K |
|
|
IPXL
6
DELISTED
Impax Laboratories, Inc.
IPXL
| $3.89M | 6.76% | 164,156 +93,921 | +134% | +$2.23M |
|
7
UnitedHealth
UNH
$281B
| $3.88M | 6.75% | 27,728 +4,080 | +17% | +$571K |
|
8
Incyte
INCY
$16.5B
| $3.53M | 6.13% | 37,407 +11,897 | +47% | +$1.12M |
|
9
Jazz Pharmaceuticals
JAZZ
$7.75B
| $3.43M | 5.96% | 28,229 -11,311 | -29% | -$1.37M |
|
|
10
Eli Lilly
LLY
$657B
| $2.65M | 4.61% | 33,029 -25,936 | -44% | -$2.08M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $1.91M | 3.31% | 37,644 +6,973 | +23% | +$353K |
|
|
SGYP
12
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $1.87M | 3.25% | 339,068 +40,878 | +14% | +$225K |
|
13
Edwards Lifesciences
EW
$47.8B
| $1.68M | 2.92% | 13,908 -14,362 | -51% | -$1.73M |
|
|
14
NovoCure
NVCR
$1.38B
| $1.34M | 2.33% | +157,176 | New | +$1.34M |
|
|
NVRO
15
DELISTED
NEVRO CORP.
NVRO
| $1.27M | 2.21% | 12,161 -38,472 | -76% | -$4.01M |
|
16
Galapagos
GLPG
$2.07B
| $404K | 0.7% | +6,250 | New | +$404K |
|
|
17
Quest Diagnostics
DGX
$20.3B
| $398K | 0.69% | 4,700 -30,143 | -87% | -$2.55M |
|
18
Glaukos
GKOS
$5.5B
| $386K | 0.67% | +10,233 | New | +$386K |
|
19
Pacira BioSciences
PCRX
$1.2B
| – | – | -41,707 | Closed | -$1.41M |
|
|
20
Teva Pharmaceuticals
TEVA
$21.1B
| – | – | -83,502 | Closed | -$4.19M |
|
|
ALR
21
DELISTED
Alere Inc
ALR
| – | – | -63,905 | Closed | -$2.66M |
|